When it comes to clinical studies, particularly those examining human abuse potential (HAP), the way participants are selected and recruited is crucial. These studies are designed to evaluate whether a substance, such as a new medication or drug, has the potential to...
This article is featured on The Association of Clinical Research Professionals (ACRP). Bradley D. Vince, DO and Sheldon H. Preskorn, MD discuss the process of developing a new molecular entity (NME) for FDA approval and strategies for establishing early efficacy. Key...
Most drugs are eliminated from the body through some combination of vital organs, such as the small intestine, liver and/or kidneys. The impaired function of either the liver or the kidney can significantly impact a drug’s pharmacokinetics (PK), influencing its...
At Dr. Vince Clinical Research we offer full-service Phase I-II trial execution that not only generates SMARTER FASTER DATA®, but does so through a building design that promotes greater overall wellness and long-term environmental sustainability. In order to discover...
At Dr. Vince Clinical Research, we utilize a forward-thinking model for Phase I studies supported by foundational pillars that completely reimagine research standards. Every inch of our facilities, and every step in our procedures, is intentionally designed, enabled...
CROs have a retention problem. Nearly 1 in 5 research sites have a turnover rate above 30%, and it has become increasingly difficult for many facilities and site management organizations to build a robust roster of specialized and proven professionals (1). While the...
Recent Comments